top of page

Patient preference studies

Qualitative and quantitative studies to elicit patient, caregiver, physician, or other stakeholder preferences

Patient preference research for informing development and marketing of innovative therapies

Unique expertise in patient preference methodologies. We are leaders in patient preference research and have expertise in qualitative and quantitative techniques, including the key methods such as discrete choice experiments (DCE),  best-worst scaling (BWS), thresholding, and swing weighting.

pexels-yuting-gao-1557547.jpg

Real-world patient insights

Interview and focus group studies to gain insight in unmet need, disease burden, and other critical aspects influencing market authorization and access decisions

We have expertise in developing and conducting qualitative studies both for standalone purposes and for supporting the design and interpretation of quantitative patient preference studies. Our researchers have developed qualitative studies that were included in regulatory submissions.

erik-mclean-oPWGhqBPNI0-unsplash.jpg

Patient-centered clinical trial design

Our patient preference, patient insight, and benefit-risk studies can be used for ensuring patient-centred clinical trial design

Selection of endpoints that matter to patients

Understand patient value of improvements in patient reported outcome measures

Ensure positive benefit-risk profile from patient perspective

Optimize clinical trial design from the patient perspective

pexels-ethan-sees-2853432.jpg

Benefit-risk assessment

Structured benefit-risk assessments that can incorporate patient preferences into the analysis

Our staff has rare experience in developing benefit-risk assessments that were included in EMA and FDA submissions. Techniques developed by our scientists are endorsed by EMA and FDA as fit-for-purpose in informing regulatory decisions.

pexels-cedric-fauntleroy-4270078.jpg

Training

Development, execution, and evaluation of training programs for both technical and non-technical aspects of patient preference research, and benefit-risk assessment

Training by experienced and accredited educators. We have trained teams at top-20 pharmaceutical companies in the use of patient preferences, multi-criteria decision analysis (MCDA), and benefit-risk assessment – both in technical and non-technical aspects.

pexels-antoni-shkraba-5215017.jpg

Patient preference studies

Qualitative and quantitative studies to elicit patient, caregiver, physician, or other stakeholder preferences

Patient preference research for informing development and marketing of innovative therapies

Unique expertise in patient preference methodologies. We are leaders in patient preference research and have expertise in qualitative and quantitative techniques, including the key methods such as discrete choice experiments (DCE),  best-worst scaling (BWS), thresholding, and swing weighting.

pexels-yuting-gao-1557547.jpg

Real-world patient insights

Interview and focus group studies to gain insight in unmet need, disease burden, and other critical aspects influencing market authorization and access decisions

We have expertise in developing and conducting qualitative studies both for standalone purposes and for supporting the design and interpretation of quantitative patient preference studies. Our researchers have developed qualitative studies that were included in regulatory submissions.

erik-mclean-oPWGhqBPNI0-unsplash.jpg

Patient-centered clinical trial design

Our patient preference, patient insight, and benefit-risk studies can be used for ensuring patient-centred clinical trial design

Selection of endpoints that matter to patients

Understand patient value of improvements in patient reported outcome measures

Ensure positive benefit-risk profile from patient perspective

Optimize clinical trial design from the patient perspective

pexels-lil-artsy-1194775.jpg

Benefit-risk assessment

Structured benefit-risk assessments that can incorporate patient preferences into the analysis

Our staff has rare experience in developing benefit-risk assessments that were included in EMA and FDA submissions. Techniques developed by our scientists are endorsed by EMA and FDA as fit-for-purpose in informing regulatory decisions.

pexels-gustavo-fring-6285367.jpg

Training vaihda kuva johonkin, missä paljon porukkaa

Development, execution, and evaluation of training programs for both technical and non-technical aspects of patient preference research, and benefit-risk assessment

Training by experienced and accredited educators. We have trained teams at top-20 pharmaceutical companies in the use of patient preferences, multi-criteria decision analysis (MCDA), and benefit-risk assessment – both in technical and non-technical aspects.

bottom of page